natgillin/translations-raw huggingface dataset:
Du må ikke få Zoledronsyre Hospira - hvis du er allergisk over for zoledronsyre, andre bisfosfonater eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i punkt 6) - hvis du har hypokalcæmi (dvs. du har for lavt indhold af calcium i blodet). 
You must not be given Zoledronic Acid Hospira: - if you are allergic to zoledronic acid, other bisphosphonates or any of the other ingredients of this medicine (listed in section 6).
• Amning (se pkt. 
•Breast-feeding (see section 4.6).
Mannitol, natriumcitrat og vand til injektionsvæsker. 
Mannitol, sodium citrate and water for injections.
3,0 mg* zoledronsyre 
3.0 mg* zoledronic acid
- Ud fra et mikrobiologisk synspunkt skal produktet anvendes straks efter åbning. 
- From a microbiological point of view, the product should be used immediately.
Hvordan skal Zoledronsyre Hospira opbevares 
How Zoledronic Acid Hospira is given
Efter markedsføring af produktet er en bivirkning kaldet osteonekrose i kæben (knogleskade i kæben) blevet set hos patienter behandlet med Zoledronsyre Hospira (zoledronsyre) mod osteoporose. 
A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported in the post-marketing setting in patients receiving zoledronic acid for osteoporosis.
- hvis du ammer. 
− if you are breast-feeding.
Følgende konventionelle klassifikation er anvendt: Meget almindelig (1/10), almindelig (1/100 til <1/10), ikke almindelig (1/1.000 til <1/100), sjælden (1/10.000 til <1/1.000), meget sjælden 
The following conventional classification is used: very common ( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100), rare ( 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Hvis opløsningen opbevares i køleskab, skal den tempereres til stuetemperatur inden administration. 
If refrigerated, allow the refrigerated solution to reach room temperature before administration.
Bradykardi, hjertearytmi (sekundært til hypokalcæmi) Luftveje, thorax og mediastinum Ikke almindelig: 
Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia) Respiratory, thoracic and mediastinal disorders Uncommon: Dyspnoea, cough, bronchoconstriction Rare
Almindelig Atrieflimren Ikke almindelig 
Common Atrial fibrillation Uncommon Palpitations
Er du i tvivl, så spørg lægen eller sygeplejersken. 
− If you have any further questions, ask your doctor, pharmacist or nurse.
Tabel med liste over bivirkninger 
Tabulated list of adverse reactions
Effektresultaterne kan ses i tabel 3. 
Efficacy results are provided in Table 3.
Sjældne (kan forekomme hos op til 1 ud af 1.000 patienter) Usædvanlige brud på lårbensknoglen, primært hos patienter i langtidsbehandling for osteoporose, kan forekomme i sjældne tilfælde. 
Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely.
For at undgå eventuelle uforligeligheder skal der som infusionsvæske til fortynding enten bruges natriumchlorid 9 mg/ml (0,9%) opløsning til injektion eller 5% w/v glucoseopløsning. 
To avoid potential incompatibilities, the infusion solution used for dilution must be either sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution.
Kun til engangsbrug. 
− For single use only.
Andel af patienter med SRE'er p-værdi Mediantid til SRE (dage) 
p-value Median time to SRE (days)
Efter første åbning: Ud fra et mikrobiologisk synspunkt skal opløsningen til infusion anvendes straks. 
After first opening: From a microbiological point of view, the product should be used immediately.
Én ml koncentrat indeholder 0,8 mg zoledronsyre (som monohydrat). 
One ml concentrate contains 0.8 mg zoledronic acid (as monohydrate).
Overvågning 
Monitoring test
- Øvrige indholdsstoffer: mannitol, natriumcitrat, natriumchlorid og vand til injektionsvæsker. 
− The other ingredients are: mannitol, sodium citrate, sodium chloride and water for injections.
Interstitiel lungesygdom 
Musculoskeletal pain
Osteonekrose af kæberne er blevet rapporteret efter markedsføring hos patienter behandlet med zoledronsyre for osteoporose (se pkt. 
ONJ has been reported in the post-marketing setting in patients receiving zoledronic acid for osteoporosis (see section 4.8).
5.1) var den generelle forekomst af atrieflimren 2,5% (96 ud af 3.852) og 1,9% (75 ud af 3.852) hos patienter, som fik henholdsvis zoledronsyre og placebo. 
In the HORIZON - Pivotal Fracture Trial [PFT] (see section 5.1), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid and placebo, respectively.
Almindelig (kan forekomme hos op til 1ud af 10 patienter): - Svært nedsat nyrefunktion (vil normalt blive afgjort af din læge ved hjælp af en speciel type blodprøver). 
− Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).
Zoledronsyre Hospira 4 mg/5 ml koncentrat til infusionsvæske, opløsning Zoledronsyre 
Zoledronic Acid Hospira 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronsyre er kontraindikeret hos kvinder, der ammer (se pkt. 
Zoledronic acid is contraindicated in breast-feeding women (see section 4.3).
<10% af maksimalkoncentrationen efter 4 timer og <1% af maksimalkoncentrationen efter 24 timer, med en efterfølgende forlænget periode med meget lave koncentrationer der ikke overstiger 0,1% af den maksimale koncentration inden den 2. infusion af zoledronsyre på dag 28. 
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Zoledronsyre Hospira er en klar, farveløs opløsning. 
What Zoledronic Acid Hospira looks like and contents of the pack Zoledronic Acid Hospira is a clear and colourless solution.
- Det uåbnede hætteglas kræver ingen særlige forholdsregler vedrørende opbevaringen. 
− The unopened vial does not require any specific storage conditions.
Tabel 5: Effektresultater (patienter med brystcancer eller multipelt myelom) Enhver SRE (+TIH) 
Table 5: Efficacy results (breast cancer and multiple myeloma patients)
Et hætteglas med 5 ml koncentrat indeholder 4 mg zoledronsyre (som monohydrat). 
One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate).
Pruritus, udslæt (inklusive erythematøst og makuløst udslæt), øget svedtendens Knogler, led, muskler og bindevæv Almindelig: 
Nausea, vomiting, decreased appetite Uncommon: Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth Skin and subcutaneous tissue disorders Uncommon: Pruritus, rash (including erythematous and macular rash), increased sweating Musculoskeletal and connective tissue disorders Common:
Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er noget, du er i tvivl om. 
Check with your doctor or nurse if you are not sure.
Almindelig Hovedpine, svimmelhed Ikke almindelig 
Uncommon Hypertension, flushing Not known**
Før indgift af zoledronsyre skal patienterne vurderes med henblik på at sikre, de er vel hydrerede. 
Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated.
Zoledronsyre Hospira frarådes til personer under 18 år, da brug af Zoledronsyre Hospira til børn og unge ikke er undersøgt. 
The use of Zoledronic Acid Hospira in children and adolescents has not been studied.
Derudover har der været sporadiske rapporter om osteonekrose af andre steder, inklusive hoften og femur. 
Additionally, there have been sporadic reports of osteonecrosis of other sites, including the hip and femur, reported predominantly in adult cancer patients treated with Zoledronic Acid Hospira.
- For at undgå væskemangel vil din læge anbefale at du drikker drikke rigeligt med vand inden behandlingerne. 
− Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.
Almindelig Okulær hyperæmi Ikke almindelig 
Common Ocular hyperaemia Uncommon Conjunctivitis, eye pain Rare
Zoledronsyre Hospira indeholder - Aktivt stof: Det aktive stof i Zoledronsyre Hospira 4 mg/100 ml infusionsvæske, opløsning er zoledronsyre. 
− The active substance of Zoledronic Acid Hospira 4 mg/100 ml solution for infusion is zoledronic acid.
Sjælden (kan forekomme hos op til 1 ud af 1.000 patienter): -Langsomhjerterytme. 
Rare (may affect up to 1 in 1,000 people):
4.5), strålebehandling i nakke og hoved, kortikosteroider. 
- Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to neck and head, corticosteroids.
Zoledronsyre Hospira infusionsvæske, opløsning må ikke blandes med andre infusionsvæsker og bør indgives som en enkelt intravenøs opløsning i en separat infusionsslange. 
Zoledronic Acid Hospira must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Zoledronsyre Hospira 4 mg/100 ml infusionsvæske, opløsning Zoledronsyre 
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion Zoledronic acid
Hver pose af 100 ml indeholder 5 mg zoledronsyre (som monohydrat). 
Each bag of 100 ml contains 5 mg zoledronic acid (as monohydrate).
Zoledronsyre Hospira 5 mg/100 ml (vises i en cirkel) infusionsvæske, opløsning Zoledronsyre 
Zoledronic Acid Hospira 5 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Zoledronsyre Hospira 5 mg/100 ml infusionsvæske, opløsning Zoledronsyre 
Zoledronic Acid Hospira 5 mg/100 ml solution for infusion Zoledronic acid
Zoledronsyre Hospira 4 mg/100 ml (vises i en cirkel) infusionsvæske, opløsning Zoledronsyre 
Zoledronic Acid Hospira 4 mg/100 ml (to appear in roundel) solution for infusion Zoledronic acid
Hver ml af opløsningen indeholder 0,05 mg vandigt zoledronsyre (som monohydrat). 
Each ml of the solution contains 0.05 mg zoledronic acid anhydrous (as monohydrate).
Almindelig: Hypofosfatæmi 
Hypophosphataemia
Zoledronsyre Hospira leveres i pakninger med 1 hætteglas. 
Zoledronic Acid Hospira is supplied as packs containing 1 vial.
- Øvrige indholdsstoffer: mannitol, natriumcitrat, vand til injektionsvæsker. 
− The other ingredients are: mannitol, sodium citrate, water for injections.
Ikke almindelig (kan forekomme hos op til 1 ud af 100 patienter): - Overfølsomhedsreaktioner. 
Uncommon (may affect up to 1 in 100 people):
Mave-tarm-kanalen Almindelig: 
Cardiac disorders Common:
Opløsninger, som opbevares i køleskab, skal have stuetemperatur før administration. 
Allow the refrigerated solution to reach room temperature before administration.
Fritaget fra krav om brailleskrift. 
INFORMATION IN BRAILLE Justification for not including Braille accepted.
- Øvrige indholdsstoffer: mannitol, natriumcitrat og vand til injektionsvæsker. 
- The other ingredients are mannitol, sodium citrate and water for injections.
- Tidligere tandsygdomme, dårlig mundhygiejne, paradentose, invasive tandbehandlinger (fx tandudtrækninger) og dårligt tilpassede tandproteser. 
- History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures
Dyspepsi, øvre mavesmerter, mavesmerter, gastroøsofageal reflukssygdom, forstoppelse, mundtørhed, øsofagit, tandpine, gastrit 
Common Nausea, vomiting, diarrhoea Uncommon Dyspepsia, abdominal pain upper, abdominal pain, gastroesophageal reflux disease, constipation, dry mouth, oesophagitis, toothache, gastritis Skin and subcutaneous tissue disorders Uncommon Rash, hyperhidrosis, pruritus, erythema Musculoskeletal and connective tissue Common Myalgia, arthralgia, bone pain, back pain,
Følgende bør overvejes når risikoen for at udvikle osteonekrose af kæberne skal vurderes hos den enkelte patient: - Styrken af det lægemiddel, der hæmmer knogleresorption (øget risiko ved højpotente stoffer), 
The following should be considered when evaluating a patient's risk of developing ONJ: - Potency of the medicinal product that inhibits bone resorption (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bone resorption therapy.
Sådan får du Zoledronsyre Hospira 
How to store Zoledronic Acid Hospira
Konjunktivit, øjensmerter 
Eye disorders
- Forhøjet blodtryk, åndenød, svimmelhed, angst, søvnforstyrrelser, smagsforstyrrelser, rysten, 
− High blood pressure, shortness of breath, dizziness,anxiety,sleep disturbances,taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhea, constipation, abdominal pain, dry mouth.
Akut nyresvigt, hæmaturi, proteinuri 
Uncommon: Acute renal failure, haematuria, proteinuria Rare
En pose med 100 ml indeholder 4 mg zoledronsyre (som monohydrat). 
One bag with 100 ml contains 4 mg zoledronic acid (as monohydrate).
Trombocytopeni, leukopeni 
Uncommon: Thrombocytopenia, leukopenia Rare:
Natriumcitrat 
− Sleepiness
Almindelig: Abdominalsmerter 
disorders pain in extremity
Influenza, nasofaryngit 
Uncommon Influenza, nasopharyngitis
Nyrer og urinveje Almindelig: 
Renal and urinary disorders
Én pose indeholder 4 mg zoledronsyre (som monohydrat). 
One bag contains 4 mg of zoledronic acid (as monohydrate).
- hvis du er overfølsom (allergisk) over for zoledronsyre, et andet bisfosfonat (den gruppe af stoffer, 
− if you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of Zoledronic Acid Hospira.
En ml opløsning indeholder 0,04 mg zoledronsyre (som monohydrat). 
One ml solution contains 0.04 mg zoledronic acid (as monohydrate).
4.8), specielt hos patienter med eksisterende nedsat nyrefunktion eller andre risici såsom fremskreden alder, samtidig anvendelse af nefrotoksiske lægemidler, samtidig dialysebehandling (se pkt. 
Renal impairment has been observed following the administration of zoledronic acid (see section 4.8), especially in patients with pre-existing renal dysfunction or other risks including advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy (see section 4.5), or dehydration occurring after zoledronic acid administration.
Tilberedelse og indgift af Zoledronsyre Hospira 
Other medicines and Zoledronic Acid Hospira
Det skal du vide om Zoledronsyre Hospira Sådan bliver du behandlet med Zoledronsyre Hospira Bivirkninger 
What Zoledronic Acid Hospira is and what it is used for What you need to know before you are given Zoledronic Acid Hospira How Zoledronic Acid Hospira is used Possible side effects
- Opbevar Zoledronsyre Hospira utilgængeligt for børn. 
− Keep Zoledronic Acid Hospira out of the reach and sight of children.
Du må ikke få Zoledronsyre Hospira: - hvis du ammer. 
You should not be given Zoledronic Acid Hospira:
Zoledronsyre Hospira 4 mg/5 ml koncentrat til infusionsvæske, opløsning. 
Zoledronic Acid Hospira 4 mg/5 ml concentrate for solution for infusion
Sjælden Hypofosfatæmi 
Uncommon Insomnia
En ml opløsning indeholder 0,05 mg zoledronsyre (som monohydrat). 
One ml solution contains 0.05 mg zoledronic acid (as monohydrate).
Letargi, paræstesi, somnolens (søvnlignende bevidsthedssvækkelse), tremor, synkope, dysgeusi 
tremor, syncope, dysgeusia
Zoledronsyre 4 mg 
4 mg
Pancytopeni 
Breast-feeding
Osteonekrose af øregangen 
Osteonecrosis of the external auditory canal
Almindelige (kan forekomme hos op til 1 ud af 10 patienter) Uregelmæssig hjerterytme (puls), kaldet atrieflimren, er set hos patienter behandlet med zoledronsyre for post-menopausal osteoporose. 
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for the treatment of postmenopausal osteoporosis.
Zoledronsyre Hospira 5 mg/100 ml infusionsvæske, opløsning. 
Zoledronic Acid Hospira 5 mg/100 ml solution for infusion
Zoledronsyre Hospira 4 mg/100 ml infusionsvæske, opløsning. 
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion
Tabel 3: Effektresultater (patienter med prostatacancer i hormonbehandling) Enhver SRE (+TIH) 
Table 3: Efficacy results (prostate cancer patients receiving hormonal therapy)
Et hætteglas indeholder 4 mg zoledronsyre (som monohydrat). 
One vial contains 4 mg zoledronic acid (as monohydrate).
En pose med 100 ml opløsning indeholder 4 mg zoledronsyre (som monohydrat). 
Each bag with 100 ml of solution contains 4 mg zoledronic acid (as monohydrate).
Nervesystemet Almindelig: Hovedpine Ikke almindelig: 
Psychiatric disorders Uncommon: Anxiety, sleep disturbance Rare:
Nyrer og urinveje Almindelig: Nedsat nyrefunktion Ikke almindelig: 
Pancytopenia Immune system disorders Uncommon: Hypersensitivity reaction Rare:
Almindelig: Takykardi Luftveje, thorax og mediastinum Almindelig: Nasopharyngitis Mave-tarm-kanalen Meget almindelig: 
Bone pain, myalgia, arthralgia, generalised pain Uncommon: Muscle spasms, osteonecrosis of the jaw Very rare:
Meget sjælden (kan forekomme hos op til 1 ud af 10.000 patienter): - Som en konsekvens af lave calcium-værdier: Kramper, følelsesløshed og tetani (sekundære symptomer på hypokalcæmi). 
− As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Brug af anden medicin og Zoledronsyre Hospira Fortæl det altid til lægen, hvis du bruger anden medicin eller har brugt det for nylig. 
Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
- Nældefeber. 
− Chest pain.
Hver pose indeholder 100 ml opløsning, indeholdende 5 mg zoledronsyre (som monohydrat). 
Each bag with 100 ml of solution contains 5 mg zoledronic acid (as monohydrate).
Efter markedsføringen er følgende bivirkninger blevet rapporteret (hyppighed sjælden): Atypiske subtrokantære og diafyseale femurfrakturer (bisfosfonat klasseeffekt). 
Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction).
Almindelig Kvalme, opkastning, diarré Ikke almindelig 
Psychiatric disorders Uncommon: Anxiety, sleep disturbance
Almindelig: Hovedpine 
Patients with hepatic impairment
Denanbefalededosisvedhyperkalcæmi(albuminkorrigeretserumcalcium≥ 12,0mg/dleller 
The recommended dose in hypercalcaemia (albumin-corrected serum calcium ≥ 12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.
Under disse omstændigheder bør hensigtsmæssig og hurtig symptomatisk behandling administreres. 
Under these circumstances, appropriate and rapid symptomatic treatment should be administered.
En tredje dosis skal gives to måneder derefter. 
A third dose should be administered 2 months thereafter.
Kvæg (køer og kvier). 
Cattle (cows and heifers).
Dette veterinærlægemiddel indeholder mineralolie. 
This veterinary medicinal product contains mineral oil.
En dosis (2 ml) indeholder: 
One dose (2 ml) contains:
ATCvet-kode: QI02 AB17. 
ATCvet code: QI02AB17.
Dato for første markedsføringstilladelse: 11/02/2009 Dato for seneste fornyelse af markedsføringstilladelse: 10/02/2014 
Date of first authorisation: 11/02/2009 Date of last renewal: 10/02/2014
Tilbageholdelsestid: Nul dage. 
Withdrawal period: Zero days.
En beslutning om at bruge vaccinen før eller efter ethvert andet veterinært lægemiddel bør derfor træffes i hvert enkelt tilfælde. 
A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Det komplette immuniseringsprogram bør gentages ved hver drægtighed. 
The full immunisation program should be repeated with each gestation.
Batch {nummer} 
Batch{number}
Injektionerne bør helst foretages på skiftevis den ene og den anden side af halsen. 
The injections should be preferably administered on the alternate sides of the neck.
Yderligere information om dette veterinærlægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu 
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu).
Opbevares og transporteres nedkølet (2 til 8 °C) og beskyttet mod lys. 
Store and transport refrigerated (2 °C - 8 °C) and protected from light.
Uforsætlig injektion er farlig - læs indlægssedlen inden brug. 
Accidental injection is dangerous - read the package leaflet before use.
Opbevaringstid for veterinærlægemidlet i salgspakning: 18 måneder. 
Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Det komplette immuniseringsprogram bevirker en immunitet fra ca. 13. dag efter første injektion til ca. 78. dag efter tredje injektion. 
The full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection.
Hele besætningen bør immuniseres. 
The whole herd should be immunised.
Benzylalkohol Flydende paraffin Sorbitanmonooleat Polysorbat 80 
Benzyl alcohol Liquid paraffin Sorbitan monooleate Polysorbate 80
Der foreligger ingen oplysninger om sikkerhed og virkning ved brug af vaccinen sammen med andre veterinære lægemidler. 
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
I visse tilfælde kan der også forekomme smerter på inokuleringsstedet, som forsvinder af sig selv efter højst 4 dage. 
In some cases, there may also be pain at the inoculation site that spontaneously subsides in a maximum of 4 days.
Meget sjældne bivirkninger: 
Very rare adverse reactions:
Indgiv en dosis (2 ml) ved dyb intramuskulær injektion i nakkemusklerne 45 dage før den forventede fødselsdato og en måned derefter administrér en anden dosis (mindst 10 dage før kælvning). 
Administer one dose (2 ml) by deep intramuscular injection in the neck muscles at 45 days before the expected parturition date and 1 month thereafter administer a second dose (at least 10 days before calving).
Hjælpestofferne (inclusive adjuvanter) som er anført i punkt 6.1 af SPC'et er enten tilladte hjælpestoffer, hvor tabel 1 i bilaget til Kommissionens forordning (EU) Nr. 37/2010 indikerer at MRL-værdier ikke er påkrævet eller som ikke anses for at være omfattet af Forordning (EF) nr. 470/2009, når de anvendes i et veterinærlægemiddel. 
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Må ikke bruges efter den udløbsdato, der står på etiketten after UDL.D. 
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Hvis du ved et uheld injiceres med dette veterinærlægemiddel, skal du søge omgående lægehjælp, også selvom det kun drejer sig om en meget lille mængde, og tag indlægssedlen med dig. 
If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.
Flydende paraffin: 18,2 mg 
Liquid paraffin: 18.2 mg
Overdosering (symptomer, nødforanstaltninger, modgift): 
Overdose (symptoms, emergency procedures, antidotes):
Laboratorios Hipra, S.A. (CIAMER) Carretera C-63, km 48.300, Polígono Industrial El Rieral 17170 Amer (Girona) Spanien 
Laboratorios Hipra, S.A. (CIAMER) Carretera C-63, km 48.300, Polígono Industrial El Rieral 17170 Amer (Girona) Spain
Elfenbensfarvet homogen emulsion. 
Ivory-coloured homogeneous emulsion.
Det kan hovedsagelig dreje sig om: hævelser (op til 5 cm2 i gennemsnit), som forsvinder efter højst 1 til 2 uger. 
They would mainly be: swelling (up to 5 cm2 on average), which disappears within 1 or 2 weeks at most.